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We performed a multicentre retrospective cohort study 
including 606,649 acute inpatient episodes at 10 
European hospitals in 2010 and 2011 to estimate the 
impact of antimicrobial resistance on hospital mortal-
ity, excess length of stay (LOS) and cost. Bloodstream 
infections (BSI) caused by third-generation cephalo-
sporin-resistant Enterobacteriaceae (3GCRE), meticil-
lin-susceptible (MSSA) and -resistant Staphylococcus 
aureus (MRSA) increased the daily risk of hospital death 
(adjusted hazard ratio (HR) = 1.80; 95% confidence 
interval (CI): 1.34–2.42, HR = 1.81; 95% CI: 1.49–2.20 
and HR = 2.42; 95% CI: 1.66–3.51, respectively) and 
prolonged LOS (9.3 days; 95% CI: 9.2–9.4, 11.5 days; 
95% CI: 11.5–11.6 and 13.3 days; 95% CI: 13.2–13.4, 
respectively). BSI with third-generation cephalosporin-
susceptible Enterobacteriaceae (3GCSE) significantly 
increased LOS (5.9 days; 95% CI: 5.8–5.9) but not 
hazard of death (1.16; 95% CI: 0.98–1.36). 3GCRE sig-
nificantly increased the hazard of death (1.63; 95% 
CI: 1.13–2.35), excess LOS (4.9 days; 95% CI: 1.1–8.7) 
and cost compared with susceptible strains, whereas 
meticillin resistance did not. The annual cost of 3GCRE 
BSI was higher than of MRSA BSI. While BSI with  S. 
aureus  had greater impact on mortality, excess LOS 
and cost than  Enterobacteriaceae per infection, the 
impact of antimicrobial resistance was greater for 
Enterobacteriaceae.
Introduction
Antimicrobial resistance (AMR) represents a significant 
global threat [1,2]. Response to this threat requires 
coordinated international interventions likely to involve 
commitment of substantial resources [3]. It is useful to 
obtain accurate estimates of the health and economic 
burden of AMR as these illustrate opportunities to 
improve health and reduce costs. Comprehensive data 
remain scarce; a recent World Health Organization 
(WHO) systematic review identified a “lack of properly 
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designed and conducted economic studies comparing 
the resource use associated with resistant versus non-
resistant pathogens” [1].
Studies to determine health outcomes of infections 
with community and hospital onset must adequately 
account for confounding, the timing of infection (time 
dependency) and simultaneous impact on risk of death 
and discharge (competing risks), but also analyse a 
sample of sufficient size to produce precise estimates 
[4,5]. Furthermore, although the major determinant 
of the economic burden of such infections from the 
hospital perspective is the number of bed-days they 
consume, it is challenging to produce an appropriate 
economic valuation of each marginal bed-day [6].
Given the widespread dissemination of meticillin 
resistance among Staphylococcus aureus and resist-
ance to third-generation cephalosporins among 
Enterobacteriaceae [7], we focused on these bacteria 
and resistance phenotypes. We examined bloodstream 
infections (BSI) because of their relatively high inci-
dence, clinical impact and diagnostic certainty. We 
were interested in costs from the hospital perspective 
because this is the perspective from which decisions 
must be made to allocate resources to interven-
tions such as antimicrobial stewardship and infection 
control.
Objectives
We sought to apply state-of-the-art methods to obtain 
unbiased and adjusted estimates of the excess length 
of stay (LOS), hospital mortality, and cost (from the 
hospital perspective) attributable to BSI caused by S. 
aureus and Enterobacteriaceae in European hospitals, 
and to compare the impact of antimicrobial non-sus-
ceptible versus susceptible strains.
Methods
Study design
We performed a multicentre, retrospective cohort study. 
The cohort consisted of all acute-care admissions at 10 
European hospitals from 1 January 2010 to 31 December 
2011. BSI were the time-varying exposure of interest 
and their impact on hospital mortality, LOS and cost 
was evaluated. Independent analyses were performed 
for BSI due to S. aureus and Enterobacteriaceae.
This report was formulated in accordance with the 
STROBE Statement [8].
Setting
A convenience sample of 10 European hospitals partici-
pated: three from Italy, two each from Germany and the 
United Kingdom, and one each from France, Spain and 
Switzerland. These participants were selected from a 
list of interested sites using a questionnaire address-
ing microbiological methods and clinical informatics. 
Hospitals were eligible if able to extract the required 
data from institutional databases. All eligible hospitals 
were included.
Participants
We retrospectively identified all inpatient acute-care 
episodes lasting more than one calendar day that 
started during the study period. We excluded ambu-
latory, hospital-in-the-home and non-acute care epi-
sodes as well as emergency consultations without 
consequent hospital admission. There was no age 
limit. For patients with multiple admissions during the 
study period, only the first admission was included.
Exposures
We considered four exposures defined by causative 
bacteria and antimicrobial susceptibility. Escherichia 
coli, Klebsiella spp. or Proteus spp. strains causing 
BSI were classified as third-generation cephalosporin-
susceptible Enterobacteriaceae (3GCSE) or third-
generation cephalosporin-non-susceptible (3GCRE). 
Non-susceptibility to third-generation cephalosporins 
was defined as intermediate susceptibility or resist-
ance to ceftazidime and/or one of cefotaxime, ceftriax-
one or cefpodoxime. S. aureus strains causing BSI were 
classified as meticillin-susceptible (MSSA) or meticil-
lin-resistant (MRSA). BSI was defined by one or more 
blood cultures with growth of the relevant bacteria.
Outcomes
The two primary outcomes were hospital mortality and 
excess LOS in hospital. Excess LOS was used to esti-
mate costs from the hospital perspective.
Covariates
Baseline variables considered as potential confounders 
were age, sex, location prior to episode, elective/emer-
gent admission, nights hospitalised in the previous 12 
months in the same institution and 17 comorbidities 
[9]. The Charlson Comorbidity Index was computed for 
descriptive purposes, but comorbidities were included 
in the analyses as individual covariates. Two time-var-
ying covariates were considered while patients were at 
risk for BSI: admission to an intensive care unit (ICU) 
and surgical procedure. To estimate the total impact of 
infection and avoid controlling for intermediates on the 
causal pathway, we did not adjust for events occurring 
after BSI onset, such as antibiotic exposure.
BSI were categorised as hospital-onset if detected 
after the first three inpatient calendar days [10], if 
the patient was transferred from a non-acute ward 
or another hospital, or if the patient was born during 
the current admission. All others were categorised as 
community-onset.
Data collection
One investigator from each site was trained in stand-
ardised data collection. Information technicians from 
each participating hospital extracted data from the 
hospital databases. Comorbidities were extracted 
using a validated algorithm based on ICD-9-CM and 
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ICD-10 codes [11]. Each dataset was reviewed for inter-
nal consistency and external plausibility by the cen-
tral coordinating team, with potential errors triggering 
review by the local investigators.
Microbiological methods
Antimicrobial susceptibility testing was performed 
as per routine laboratory methods at each hospital. 
All laboratories participated in national or interna-
tional quality assurance programmes and adhered to 
contemporary guidelines from the following bodies: 
Clinical and Laboratory Standards Institute (CLSI) for 
seven sites), European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) for three sites, 
Antibiogram Committee of the French Microbiology 
Society (CA-SFM) for one site, British Society for 
Antimicrobial Chemotherapy (BSAC) for one site, 
and Deutsche Industrie Norm (DIN)-Medizinische 
Mikrobiologie for one site. Three sites used more than 
one guideline during the study period. Nine sites per-
formed one or more MRSA confirmatory tests: oxacil-
lin minimum inhibitory concentration (MIC) test (n = 6), 
mecA PCR (n = 4), and penicillin binding protein 2a 
(PBP2a) agglutination (n = 4). The site that did not 
perform these tests used disc diffusion (BSAC proto-
col) and the VITEK2 system with the AST-P578 panel 
(bioMérieux, Lyon, France). Confirmatory testing for 
extended-spectrum beta-lactamase (ESBL) produc-
tion was performed by seven sites but not included 
in our definition of third-generation cephalosporin 
susceptibility.
Sample size
The sample size calculation was based on the esti-
mated excess LOS for ESBL-positive BSI, informed by 
estimates from a pilot study [12]. We wished to find the 
number of infections such that, with a power of 80% 
and α equal to 5%, we could conclude that excess LOS 
was greater than excess LOS/2, an estimate of preci-
sion, i.e. to have sufficient power to detect a lower 
confidence limit of at least half of the point estimate. 
On the basis of incidence data from participating hos-
pitals, we expected to include approximately 1,250 
patients with BSI caused by 3GCRE, allowing estimates 
with good precision for an excess LOS of four days or 
more.
Statistical analysis
Descriptive statistics
Continuous variables are summarised as median with 
25%–75% percentile, ordinal variables as count with 
percentage. BSI incidence density was computed by 
dividing the number of events by the number of patient-
days at risk.
Estimation of mortality and excess length of stay
Two important characteristics of this dataset were 
the inclusion of time-varying exposures (BSI, surgery 
and ICU admission) and competing risks (death and 
discharge alive). We adopted the multistate model 
illustrated in Figure 1 to explicitly account for these 
characteristics [4]. Patients entered the initial state 
on admission to acute care and exited by entering one 
of two competing absorbing states (hospital death or 
discharge alive), with or without passing through one 
of two intermediate states (susceptible or non-suscep-
tible BSI). Admissions were artificially right-censored 
at day 45 to reduce the influence of outliers. We rea-
soned that patients with such prolonged admissions 
were likely to remain hospitalised for other reasons not 
influenced by BSI.
Cox proportional hazards models were used to compare 
the daily risk (hazard) of reaching the endpoint, i.e. 
hospital death, discharge alive, and the combined end-
of-stay endpoint (hospital death or discharge alive), 
between the three groups of patients (non-susceptible 
BSI, susceptible BSI and uninfected subjects). We fit-
ted three models for each possible pairwise compari-
son between these three groups. Model 1 only included 
infection status as time-dependent variable. Model 2 
adjusted for age, sex, emergent/elective admission, 
nights hospitalised in the previous 12 months and 
comorbidities. Age was centred at the cohort mean 
and divided by 10. Each comorbidity was included 
as a separate indicator variable. Model 3 addition-
ally adjusted for two time-dependent variables while 
patients were at risk for BSI: ICU admission and surgi-
cal procedure. All Cox models were stratified by hospi-
tal to account for the multicentre nature of this study 
by allowing for clustering effects and site-specific 
heterogeneity in baseline hazards. The proportional 
Figure 1
Multistate model adopted for the analysis of the burden of 
bloodstream infections caused by antimicrobial resistance, 
2010–2011
Discharge
Death
Non-susceptible
bloodstream 
infection 
Susceptible 
bloodstream 
infection
Admission
Patients entered the initial state on admission to acute care unless 
the infection date was before or equal to the admission date, in 
which case the patient was assigned directly to the appropriate 
intermediate infected state. Patients exited by entering one 
of two competing absorbing states (death or discharge alive), 
with or without passing through one of two intermediate states 
(bloodstream infection caused by susceptible or non-susceptible 
pathogens). Escherichia coli, Klebsiella spp. or Proteus spp. were 
classified as susceptible or non-susceptible to third-generation 
cephalosporins. Staphylococcus aureus was classified as 
susceptible or non-susceptible to meticillin.
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hazards assumption was checked by inspection of the 
Schoenfeld residuals. No major deviations were found.
Multistate models describe the instantaneous (in this 
case, daily) risk of transition between health states. The 
excess LOS associated with an infection was derived 
as a function of these transition probabilities [4]. We 
used the Aalen-Johansen estimators as a nonparamet-
ric estimator for the matrix of transition probabilities 
for all observed transition times [13]. The expected 
LOS (in days) was then computed by a function of the 
Aalen-Johansen estimator for the matrix of transition 
probabilities [4]. The expected change in LOS for each 
of the four BSI phenotypes was computed for each day 
of admission as the difference between the estimated 
LOS, given that BSI (the intermediate state) had or had 
not occurred up to that day. The overall change in LOS 
was computed as a weighted average of these quanti-
ties, with weighting determined by the observed distri-
bution of time to BSI onset. The expected difference in 
LOS between susceptible and resistant infections was 
produced similarly, by computing for each day the dif-
ference between the estimated LOS, given that the sus-
ceptible or resistant BSI had occurred up to that day, 
then computing a weighted average of these quantities 
determined by the observed distribution of day of BSI 
onset. Standard errors and confidence intervals were 
derived by bootstrap re-sampling runs.
Figure 2
Results of multistate models to determine excess length of stay attributable to bloodstream infection caused by different 
combinations of bacteria and susceptibility, 10 European hospitals, 2010–2011 (n = 606,649)
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LOS: length of stay; MRSA/MSSA: meticillin-resistant/susceptible Staphylococcus aureus; 3GCRE/3GCSE: third-generation cephalosporin-
resistant/susceptible Enterobacteriaceae.
The upper half in each panel (A-D) illustrates the relationship between the expected change in LOS associated with a BSI (computed daily 
by subtracting the LOS of patients that had not experienced BSI on that day from those who had) and timing of BSI onset (in days from 
admission). The lower half of each panel presents the weights used to compute the summary excess LOS, calculated using the observed 
relative frequency BSI onset each day. For all types of infections, early BSI was associated with the greatest difference in LOS.
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We adjusted excess LOS for the baseline covariates 
included in Model 2 using pseudo-observations [14]. 
Excess LOS was estimated for all possible subsets of 
the entire cohort created by removing a single patient. 
In each case, the excess LOS estimate was compared 
to the estimate derived from the full cohort; this dif-
ference or pseudo-observation contained information 
on the way in which patient-level covariates affected 
the LOS estimate. The pseudo-observations were then 
included in a generalised linear model with identity 
link and independent working covariance matrix to 
model the effect of covariates on the excess LOS. In 
practice, the regression coefficients were estimated 
using the generalized estimating equations approach 
with robust variance estimator to account for hospital-
level clustering [15]. Time-dependent covariates (Model 
3) were not included because this would have been dif-
ficult to implement and interpret. To reduce the influ-
ence of outliers, the original pseudo-observations 
were transformed using the cubic root function, simi-
lar to the common log transformation of LOS data but 
allowing for negative excess LOS.
Cost estimation
For each combination of bacterium and susceptibility, 
we computed the attributable cost of a single BSI from 
the hospital perspective as the product of excess LOS 
and the value of a bed-day [6]. We performed a Monte 
Carlo simulation with 10,000 samples to account for 
parameter uncertainty [16]. We used gamma probabil-
ity distributions to represent the excess LOS associ-
ated with each BSI, fitting these distributions to the 
unadjusted estimate from the current study (Model 
1) to best reflect our patient mix. We used log-nor-
mal distributions for two contrasting bed-day values, 
both obtained from the study hospitals as previously 
reported: an economic estimate of the opportunity cost 
of a bed-day obtained by contingent valuation and the 
accounting cost derived by dividing the total annual 
hospital budget by the number of bed-days supplied 
during the same period [17].
To estimate the annual hospital costs of each BSI, 
these marginal costs were multiplied by the expected 
number of BSI cases per year, as estimated for a hos-
pital with 450,000 bed-days using incidence densities 
calculated in the analysis here below. Results are pre-
sented as median with 95% credible interval, to two 
significant figures. A full description of data sources 
and probability distributions can be obtained from the 
corresponding author.
The cost estimation was implemented in OpenBUGS, 
version 3.2.3. Other statistical analyses were per-
formed using R, version 3.1.0 (R Foundation for 
Statistical Computing) including the etm, mvna, and 
survival packages [18].
Ethics statement
This study was approved, with a waiver for individual 
informed consent, by the human research ethics com-
mittee at each institution. 
Results
Participants
Ten public hospitals provided a cohort of 867,977 
acute-care episodes involving 606,649 patients (Table 
1). Each patient’s first episode was included in the 
analysis.
Median patient age at admission was 49 years (inter-
quartile range (IQR): 28–69); 53% were female. Median 
LOS was four days (IQR: 2–7), and 588,118 (97%) 
Table 1
Characteristics of participating hospitals, analysis of the burden of bloodstream infections caused by antimicrobial 
resistance, 2010–2011 (n = 10)
Hospital Country Type Acute beds
Study cohort
Admissions Bed-days
1 France Tertiary 1,200 64,071 424,361
2 Germany Tertiary 1,200 67,094 456,564
3 Germany Tertiary 1,332 59,517 431,384
4 Italy Tertiary 1,100 89,401 677,788
5 Italy Tertiary 1,050 53,947 373,665
6 Italy Secondary 555 27,975 183,707
7 Switzerland Tertiary 900 58,541 382,012
8 Spain Tertiary 711 50,065 336,253
9 United Kingdom Tertiary 1,050 92,569 423,534
10 United Kingdom Tertiary 936 43,469 265,392
Total 10,034 606,649 3,954,660 
Note: Admissions and bed-days relate to acute-care episodes from 2010 and 2011 included in the analysis. For patients with multiple 
admissions during the study period, only the first admission was included.
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Table 2a
Characteristics of patients in Staphylococcus aureus and Enterobacteriaceae analyses, stratified by exposure to bloodstream 
infection in 10 European hospitals, 2010–2011 (n = 606,649a)
Characteristic
Staphylococcus aureus analysis Enterobacteriaceae analysis
MRSA BSI MSSA BSI Non-infected 3GCRE BSI 3GCSE BSI Non-infected
n = 163 n = 885 n = 604,797 n = 360 n = 2,100 n = 603,972
n % n % n % n % n % n %
Demographics
Male sex 98 60.1 529 59.8 286,857 47.4 206 57.2 1,051 50.0 286,492 47.4
Median age at enrolment (IQR) 71 (59–81)
63 
(45–76)
49 
(28–69)
70 
(58–78)
70 
(56–80)
49 
(27–69)
Hospitalisation in the previous 12 months
Two or more admissions 15 9.2 40 4.5 15,708 2.6 23 6.4 112 5.3 15,660 2.6
Two or more nights hospitalised 24 14.7 72 8.1 37,468 6.2 46 12.8 229 10.9 37,354 6.2
Admission details
Emergent admission 111 68.1 639 72.2 282,382 46.7 217 60.3 1,588 75.6 281,844 46.7
Provenance
Home 134 82.2 734 82.9 500,693 82.8 303 84.2 1,848 88.0 499,942 82.8
Transfer from other hospital 16 9.8 73 8.2 16,930 2.8 21 5.8 75 3.6 16,927 2.8
Transfer from non-acute ward 2 1.2 11 1.2 2,722 0.5 1 0.3 26 1.2 2,713 0.4
Born this episode 3 1.8 7 0.8 47,414 7.8 3 0.8 29 1.4 47,397 7.8
Comorbidities
Cardiovascular disease 8 4.9 50 5.6 15,192 2.5 10 2.8 97 4.6 15,160 2.5
Congestive heart failure 29 17.8 109 12.3 22,935 3.8 32 8.9 195 9.3 22,886 3.8
Peripheral vascular disease 17 10.4 65 7.3 16,515 2.7 9 2.5 89 4.2 16,509 2.7
Cerebrovascular disease 14 8.6 77 8.7 22,908 3.8 27 7.5 165 7.9 22,836 3.8
Dementia 9 5.5 14 1.6 5,759 1.0 7 1.9 64 3.0 5,743 1.0
COPD 7 4.3 40 4.5 25,701 4.2 16 4.4 112 5.3 25,647 4.2
Connective tissue disease 2 1.2 19 2.1 5,123 0.8 2 0.6 31 1.5 5,124 0.8
Peptic ulcer disease 1 0.6 15 1.7 2,527 0.4 7 1.9 27 1.3 2,513 0.4
Mild liver disease 9 5.5 76 8.6 12,541 2.1 31 8.6 150 7.1 12,478 2.1
Diabetes without end-organ damage 23 14.1 127 14.4 38,004 6.3 28 7.8 255 12.1 37,937 6.3
Diabetes with end-organ damage 7 4.3 37 4.2 7,901 1.3 7 1.9 60 2.9 7,886 1.3
Haemiplegia or paraplegia 6 3.7 44 5.0 7,374 1.2 12 3.3 55 2.6 7,363 1.2
Renal disease 26 16.0 110 12.4 21,309 3.5 30 8.3 233 11.1 21,231 3.5
Neoplasia 13 8.0 79 8.9 43,830 7.2 45 12.5 277 13.2 43,641 7.2
Metastatic cancer 2 1.2 35 4.0 16,393 2.7 24 6.7 119 5.7 16,302 2.7
Liver diseases 2 1.2 31 3.5 3,047 0.5 11 3.1 49 2.3 3,030 0.5
HIV 0 0.0 12 1.4 1,277 0.2 1 0.3 17 0.8 1,271 0.2
Age-adjusted Charlson comorbidity 
index, median (IQR)
4 
(3–5)
3 
(1–5)
1 
(0–3)
4 
(2–5)
4 
(2–5)
1 
(0–3)
Primary diagnosis category
Certain infectious and parasitic 
diseases 20 12.3 132 14.9 13,216 2.2 53 14.7 411 19.6 13,060 2.2
Neoplasms 10 6.1 61 6.9 56,345 9.3 41 11.4 225 10.7 56,165 9.3
Blood and blood-forming organs and 
certain disorders involving the immune 
mechanism
1 0.6 6 0.7 4,400 0.7 4 1.1 9 0.4 4,399 0.7
Endocrine, nutritional and metabolic 
diseases 7 4.3 16 1.8 14,320 2.4 4 1.1 23 1.1 14,320 2.4
Mental and behavioural disorders 1 0.6 5 0.6 6,270 1.0 7 1.9 17 0.8 6,255 1.0
Nervous system, eye and adnexa, ear 
and mastoid process 3 1.8 34 3.8 40,844 6.8 5 1.4 24 1.1 40,848 6.8
BSI: bloodstream infection; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; ICU: intensive care unit; IQR: 
interquartile range; MRSA/MSSA: meticillin-resistant/susceptible Staphylococcus aureus; NA: not applicable; 3GCRE/3GCSE: third-generation 
cephalosporin-resistant/susceptible Enterobacteriaceae.
a Patients experiencing BSI caused by Enterobacteriaceae were censored from the S. aureus analysis on the day of the Enterobactericeae BSI. 
Patients experiencing BSI caused by Enterobacteriaceae on the day of admission were therefore excluded from the S. aureus analysis. The 
inverse applies for the Enterobacteriaceae analysis.
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patients were discharged alive. Of the remaining 
cohort, 10,419 (1.7%) died and 8,112 (1.3%) remained in 
hospital at the end of the study period (and underwent 
administrative censoring). Baseline characteristics are 
presented in Table 2.
BSI incidence
Of the 1,048 admissions during which S. aureus BSI 
were detected, 885 (84%) and 163 (16%) were due to 
MSSA and MRSA, respectively. The incidence den-
sity of S. aureus BSI was 0.269 episodes per 1,000 
patient-days at risk: 0.227 and 0.042 episodes per 
1,000 patient-days at risk for MSSA and MRSA BSI, 
respectively.
Of the 2,460 admissions during which 
Enterobacteriaceae BSI were detected, 2,100 (85%) and 
360 (15%) were due to 3GCSE and 3GCRE, respectively. 
The incidence density of BSI due to Enterobacteriaceae 
was 0.631 episodes per 1,000 patient-days at risk: 
0.538 and 0.092 episodes per 1,000 patient-days at 
risk for 3GCSE and 3GCRE BSI, respectively.
Hospital mortality and discharge alive
In the S. aureus analysis, 149 (16.8%) and 36 (22.1%) 
patients with MSSA and MRSA BSI died in hospital, 
respectively, compared with 10,161 (1.7%) non-infected 
patients. In the Enterobacteriaceae analysis, 212 
(10.1%) and 58 (16.1%) patients with 3GCSE and 3GCRE 
died in hospital, respectively, compared with 10,105 
(1.7%) non-infected patients.
Characteristic
Staphylococcus aureus analysis Enterobacteriaceae analysis
MRSA BSI MSSA BSI Non-infected 3GCRE BSI 3GCSE BSI Non-infected
n = 163 n = 885 n = 604,797 n = 360 n = 2,100 n = 603,972
n % n % n % n % n % n %
Circulatory system 35 21.5 201 22.7 80,361 13.3 53 14.7 221 10.5 80,324 13.3
Respiratory system 5 3.1 34 3.8 33,426 5.5 21 5.8 88 4.2 33,377 5.5
Digestive system 13 8.0 51 5.8 44,350 7.3 45 12.5 322 15.3 44,175 7.3
Skin and subcutaneous tissue 3 1.8 29 3.3 9,597 1.6 1 0.3 18 0.9 9,607 1.6
Musculoskeletal system and connective 
tissue 14 8.6 91 10.3 33,452 5.5 7 1.9 21 1.0 33,513 5.5
Genitourinary system 9 5.5 28 3.2 30,257 5.0 37 10.3 365 17.4 30,107 5.0
Pregnancy, childbirth and the 
puerperium 0 0.0 8 0.9 54,785 9.1 3 0.8 42 2.0 54,758 9.1
Certain conditions originating in the 
perinatal period 2 1.2 6 0.7 18,641 3.1 2 0.6 28 1.3 18,624 3.1
Congenital malformations, 
deformations and chromosomal 
abnormalities
2 1.2 7 0.8 12,357 2.0 1 0.3 16 0.8 12,350 2.0
Symptoms, signs and abnormal clinical 
and laboratory findings, not elsewhere 
classified
3 1.8 33 3.7 23,985 4.0 9 2.5 80 3.8 23,963 4.0
Injury, poisoning and certain other 
consequences of external causes 34 20.9 127 14.4 79,622 13.2 63 17.5 169 8.0 79,565 13.2
External causes of morbidity and 
mortality 0 0.0 3 0.3 85 0.0 0 0.0 1 0.0 87 0.0
Factors influencing health status and 
contact with health services 1 0.6 2 0.2 47,551 7.9 4 1.1 15 0.7 47,536 7.9
Epidemiological classification of BSI
Hospital onset 101 62.0 434 49.0 NA 214 59.4 780 37.1 NA
Community onset 62 38.0 451 51.0 NA 146 40.6 1,320 62.9 NA
Interventions prior to BSI
Surgical procedure 39 23.9 243 27.5 246,485 40.8 112 31.1 462 22.0 246,180 40.8
ICU admission 52 31.9 258 29.2 43,307 7.2 112 31.1 434 20.7 43,068 7.1
BSI: bloodstream infection; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; ICU: intensive care unit; IQR: 
interquartile range; MRSA/MSSA: meticillin-resistant/susceptible Staphylococcus aureus; NA: not applicable; 3GCRE/3GCSE: third-generation 
cephalosporin-resistant/susceptible Enterobacteriaceae.
a Patients experiencing BSI caused by Enterobacteriaceae were censored from the S. aureus analysis on the day of the Enterobactericeae BSI. 
Patients experiencing BSI caused by Enterobacteriaceae on the day of admission were therefore excluded from the S. aureus analysis. The 
inverse applies for the Enterobacteriaceae analysis.
Table 2b
Characteristics of patients in Staphylococcus aureus and Enterobacteriaceae analyses, stratified by exposure to bloodstream 
infection in 10 European hospitals, 2010–2011 (n = 606,649a)
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Results from the Cox proportional hazards analyses 
for death and discharge alive should be interpreted 
together (Table 3) [19].
When adjusted for potential confounders, all BSI except 
3GCSE significantly increased the hazard of hospital 
death compared with non-infected patients. This effect 
was greater for BSI due to S. aureus than BSI due to 
Enterobacteriaceae. Moreover, all BSI strongly reduced 
the hazard of discharge alive after adjustment for con-
founders, meaning that patients with BSI stayed longer 
in hospital (discharge alive HR less than 1) and were 
exposed to an increased daily risk of death throughout 
this prolonged period (mortality HR greater than 1).
Among patients with BSI due to Enterobacteriaceae, 
third-generation cephalosporin resistance significantly 
increased the hazard of death compared with third-
generation cephalosporin susceptibility (adjusted haz-
ard ratio (aHR): 1.63; 95%CI: 1.13–2.35). In contrast, 
the trend for meticillin resistance to increase haz-
ard of death amongst patients with S. aureus BSI did 
not reach statistical significance (aHR: 1.26; 95%CI: 
0.82–1.94). Similarly, while third-generation cepha-
losporin resistance significantly decreased the haz-
ard of discharge alive among patients with BSI due to 
Enterobacteriaceae, meticillin resistance showed only 
a trend in this direction among patients with BSI due 
to S. aureus.
Excess length of stay
Table 4 presents the impact of BSI on the combined 
end-of-stay endpoint (end-LOS HR) and excess LOS (in 
days) when compared with patients without BSI.
All BSI reduced the daily all-cause hazard of discharge 
or death, i.e. led to prolonged hospital stay. This pro-
longing effect was greater for BSI due to S. aureus than 
for BSI due to Enterobacteriaceae, regardless of antimi-
crobial susceptibility status. For all types of BSI, diag-
nosis early during admission was associated with the 
greatest difference in LOS (Figure 2).
Table 4 also presents the end-LOS HR and excess LOS 
for BSI caused by resistant versus susceptible patho-
gens. While third-generation cephalosporin resistance 
significantly prolonged LOS amongst patients with BSI 
due to Enterobacteriaceae, meticillin resistance did not 
for the cohort of patients with S. aureus BSI.
The adjusted excess LOS estimate (Model 2) was 
taken from the model intercept, and should therefore 
be interpreted as the excess LOS caused by infection 
in a female patient with age equal to the mean age in 
the cohort, who has no comorbidities, has not been 
in hospital for the previous year, and was admitted 
electively. Increasing age, emergency admission, male 
sex, and all comorbidities except myocardial infarction 
decreased the excess length of stay associated with all 
four BSI types.
Table 3
Results of proportional hazards models for hospital mortality and discharge alive, 10 European hospitals, 2010–2011 
(n = 606,649)
Mortality  
HR (95% CI)
Discharge alive  
HR (95% CI)
Comparison Exposure Population Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
MSSA BSI vs non-infected MSSA BSI Hospitalised patients
2.58 
(2.19–3.04)
2.41 
(2.05–2.84)
1.81 
(1.49–2.20)
0.34 
(0.31–0.37)
0.38 
(0.35–0.41)
0.54 
(0.50–0.60)
MRSA BSI vs non-infected MRSA BSI Hospitalised patients
3.18 
(2.29–4.42)
2.61 
(1.88–3.63)
2.42 
(1.66–3.51)
0.25 
(0.20–
0.32)
0.30 
(0.24–0.38)
0.45 
(0.36–0.58)
MRSA BSI vs MSSA BSI Meticillin resistance
Patients with S. 
aureus BSI
1.19 
(0.81–1.75)
1.20 
(0.82–1.76)
1.26 
(0.82–1.94)
0.74 
(0.58–
0.94)
0.73 
(0.57, 0.94)
0.80 
(0.61, 1.05)
3GCSE BSI vs non-infected 3GCSE BSI Hospitalised patients
2.25 
(1.96–2.58)
1.74 
(1.51–1.99)
1.16 
(0.98–1.36)
0.52 
(0.49–
0.54)
0.61 
(0.58–0.64)
0.80 
(0.75–0.84)
3GCRE BSI vs non-infected 3GCRE BSI Hospitalised patients
2.88 
(2.22–3.74)
2.25 
(1.73–2.92)
1.80 
(1.34–2.42)
0.37 
(0.32–
0.43)
0.43 
(0.38–0.50)
0.57 
(0.49–0.67)
3GCRE BSI vs 3GCSE BSI 3GC resistance
Patients with 
Enterobacteriaceae 
BSI
1.39 
(1.02–1.90)
1.43 
(1.05–1.96)
1.63 
(1.13–2.35)
0.63 
(0.55–0.73)
0.65 
(0.56–0.75)
0.68 
(0.57–0.81)
BSI: bloodstream infection; CI: confidence interval; HR: hazard ratio; MRSA/MSSA: meticillin-resistant/susceptible Staphylococcus aureus; 
3GC: third-generation cephalosporins; 3GCRE/3GCSE: third-generation cephalosporin-resistant/susceptible Enterobacteriaceae.
Model 1: Susceptible and resistant BSI as time-dependent covariates (univariable analysis).
Model 2: As model 1 plus adjustment for age, sex, emergent/elective admission, nights hospitalised in the previous 12 months and 
comorbidities.
Model 3: As model 2 plus admission to intensive care and surgical procedures as time-dependent covariates.
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Cost
The cost, from a hospital perspective, of each BSI and 
its annual cumulative incidence is presented in Table 5.
While 3GCSE BSI was associated with the lowest 
per-infection cost (EUR 320; 95% credible interval 
(CrI): 80–1,300; or EUR 4,000; 95% CrI 2,400–6,700, 
using economic and accounting valuations, respec-
tively), their relative frequency resulted in equal high-
est annual cost with MSSA (EUR 77,000; 95% CrI: 
19,000–300,000; or EUR 970,000; 95% CrI: 590,000–
1,600,000, using economic and accounting valuations, 
respectively).
Discussion
Per infection, S. aureus BSI had a greater effect on mor-
tality, LOS and cost than BSI due to Enterobacteriaceae. 
Meticillin resistance, however, did not significantly 
increase the hazard of death or further prolong the 
excess LOS amongst patients with S. aureus BSI. This 
contrasts with BSI due to Enterobacteriaceae, where 
third-generation-cephalosporin-resistance increased 
both the hazard of mortality and excess LOS com-
pared with susceptible strains. Furthermore, the 
annual cost, from a hospital perspective, of BSI due 
Enterobacteriaceae was equivalent to the cost of S. 
aureus BSI because the higher incidence of the former 
balanced the greater per-infection impact of the latter.
This study incorporated several novel methodological 
approaches to the recently described challenges when 
estimating the impact of AMR [5]. Multistate modelling 
is an extension of survival analysis that permits explicit 
modelling of time-varying exposures and competing 
outcomes [4], but previous applications to hospital 
epidemiology have not addressed confounding. We 
employed the flexible pseudo-observation regression 
technique to adjust these estimates for time-invariant 
potential confounders [14]. We also formally computed 
the excess LOS due to infections caused by non-sus-
ceptible compared with susceptible pathogens [20] 
rather than heuristically extrapolating this as the dif-
ference between excess LOS associated with each 
infection type compared with non-infected controls. 
Inclusion of the entire cohort of acute inpatients from 
10 hospitals over two years facilitated precise esti-
mates and avoided selection bias at patient-level, a 
risk when using matched cohorts.
We used a previously reported economic valuation of 
the opportunity cost of hospital bed-days to trans-
late excess LOS to cost of BSI from the hospital per-
spective [17], employing a Monte Carlo simulation to 
preserve uncertainty in this estimation. Substantially 
higher cost estimates were produced using an account-
ing bed-day value in order to demonstrate the impor-
tance of the costing approach used. Accounting values 
are readily obtained but only show what has histori-
cally been spent on a bed-day. As the majority of hos-
pital costs are fixed, this figure does not represent 
an amount that could be recouped should the infec-
tion be avoided. We contend that economic values, 
based on the opportunity cost of occupied bed-days, 
are appropriate for making decisions from the hospi-
tal perspective about future resource allocation for 
infection control programmes [21]. The lower cost of 
BSI, and also of AMR, obtained using the economic 
valuation provides insight into the financial challenges 
faced by hospital leadership when considering such 
Table 4
Results of proportional hazards analysis for all-cause end-length of stay and excess length of stay estimates from multistate 
models, 10 European hospitals, 2010–2011 (n = 606,649)
All-cause end-LOS  
HR (95% CI)
Excess LOS  
days (95% CI)
Comparison Exposure Population Model 1 Model 2 Model 3 Model 1 Model 2
MSSA BSI vs 
non-infected MSSA BSI Hospitalised patients
0.42 
(0.39–0.45)
0.46 
(0.43–0.49)
0.64 
(0.59–0.69)
10.35 
(9.44–11.26)
11.54 
(11.45–11.63)
MRSA BSI vs 
non-infected MRSA BSI Hospitalised patients
0.36 
(0.30–0.44)
0.42 
(0.35–0.51)
0.61 
(0.50–0.75)
12.22 
(9.89–14.55)
13.33 
(13.23–13.42)
MRSA BSI vs MSSA 
BSI
Meticillin 
resistance
Patients with S. aureus 
BSI
0.84 
(0.68–1.03)
0.83 
(0.67–1.02)
0.89 
(0.71–1.12)
1.77 
(-0.51–4.05)
2.54 
(-3.19–8.27)
3GCSE BSI vs 
non-infected 3GCSE BSI Hospitalised patients
0.57 
(0.54–0.60)
0.66 
(0.63–0.69)
0.84 
(0.80–0.89)
4.36 
(3.91–4.81)
5.87 
(5.82–5.93)
3GCRE BSI vs 
non-infected 3GCRE BSI Hospitalised patients
0.46 
(0.41–0.52)
0.53 
(0.47–0.60)
0.69 
(0.60–0.79)
7.91 
(6.66–9.16)
9.28 
(9.20–9.35)
3GCRE BSI vs 3GCSE 
BSI
3GC 
resistance
Patients with 
Enterobacteriaceae BSI
0.72 
(0.63–0.82)
0.73 
(0.64–0.83)
0.78 
(0.67–0.90)
3.53 
(2.08–4.98)
4.89 
(1.11–8.68)
BSI: bloodstream infection; CI: confidence interval; LOS: length of stay; MRSA/MSSA: meticillin-resistant/susceptible Staphylococcus aureus; 
3GC: third-generation cephalosporins; 3GCRE/3GCSE: third-generation cephalosporin-resistant/susceptible Enterobacteriaceae.
Model 1: Susceptible and resistant BSI as time-dependent covariates (univariable analysis).
Model 2: As model 1 plus adjustment for age, sex, emergent/elective admission, nights hospitalised in the previous 12 months and 
comorbidities.
Model 3: As model 2 plus admission to intensive care and surgical procedures as time-dependent covariates.
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interventions under existing funding arrangements. 
While we used the unadjusted excess LOS for this esti-
mation to best reflect the patient mix in our cohort, the 
adjusted results and covariate coefficients could be 
used to transfer our excess LOS estimate to settings 
with different patient mix.
A recent WHO systematic review of the published sci-
entific literature on the health and economic impact 
of AMR concluded that the quality of evidence on hos-
pital LOS and mortality was ‘very low’ in most cases 
[1]. It also identified a paucity of studies comparing 
hospital costs incurred by infection with resistant 
versus susceptible isolates of E. coli and K. pneumo-
niae. Our results are consistent with this review’s find-
ing that third-generation cephalosporin resistance 
is associated with increased risk of mortality among 
patients infected with E. coli or K. pneumoniae. We 
found that third-generation cephalosporin resistance 
increased the hospital LOS associated with BSI caused 
by Enterobacteriaceae, while previous reports were 
‘inconsistent’ for K. pneumoniae BSI and found no 
excess LOS for E. coli BSI. Our results do not support 
the review’s finding that infection with MRSA is associ-
ated with increased mortality and LOS compared with 
MSSA. Potential explanations include more appropri-
ate empiric antibiotic therapy during our study com-
pared with older studies and inflated estimation of 
excess LOS in previous studies due to time-dependent 
bias [5,6]. In addition, daily risk (or hazard) of death, 
as estimated here, can be expected to be smaller than 
the cumulative risks reported in the review. Although 
seemingly in contrast to older literature, our findings 
are consistent with another recent, large European 
multicentre study that found that meticillin resistance 
had no significant impact on mortality (adjusted haz-
ard ratio (aHR), 1.1; 95% CI: 0.7–1.8) or excess LOS (0.6 
days; 95% CI: −3.7 to 5.3), whereas third-generation 
cephalosporin resistance increased both risk of death 
(aHR: 2.9; 95% CI: 1.2–6.9) and excess LOS (5.0 days; 
95% CI: 0.4–10.2) [22,23]. A similarly modest impact 
of AMR has been reported in the European ICU setting 
[24].
These data should be interpreted within the context of 
the study design. The dataset was extracted retrospec-
tively from existing databases. Concerns regarding the 
quality of ICD coding data have been well described 
[25], although the Charlson comorbidity index derived 
from administrative databases has elsewhere proven 
superior to chart review [26]. We relied on routine 
antimicrobial susceptibility results performed by local 
laboratories using guidelines from five different organ-
isations. However, for MRSA and 3GCRE, there should 
not be a major misclassification bias. We were unable to 
detect community-onset healthcare-acquired infection, 
Table 5
Monte Carlo simulation results using economic and accounting bed-day values to estimate the cost of bloodstream 
infections, 10 European hospitals, 2010–2011 (n = 606,649)
Exposure Population
Excess LOS per 
BSI 
days (95% 
CrI) a
Expected 
annual 
cumulative 
incidence per 
hospital b
Estimated cost per infection  
EUR (95% CrI)
Estimated cost per hospital-
year 
EUR 1,000 (95% CrI)
  Economic   
costing c
  Accounting  
costing d
Economic 
costing c
Accounting 
costing d
MSSA BSI Hospitalised patients
10.3 
(9.3–11.5) 102
760 
(190–3,000)
9,500 
(5,800–16,000)
77 
(19–300)
970 
(590–1,600)
MRSA BSI Hospitalised patients
12.2 
(9.9–14.7) 19
890 
(220–3,600)
11,000 
(6,600–19,000)
17 
(4.1–67)
210 
(130–360)
Meticillin 
resistance
Patients with S. 
aureus BSI
1.9 
(−0.7 TO 4.6) NA
120 
(−60 TO 740)
1,600 
(−700 TO 5,000) NA NA
3GCSE BSI Hospitalised patients
4.4 
(3.9–4.9) 242
320 
(80–1,300)
4,000 
(2,400–6,700)
77 
(19–300)
970 
(590–1,600)
3GCRE BSI Hospitalised patients
7.9 
(6.6–9.4) 41
560 
(140–2,300)
7,300 
(4,300–12,000)
24 
(5–94)
300 
(180–510)
3GC 
resistance
Patients with 
Enterobacteriaceae 
BSI
3.5 
(2.1–5.1) NA
250 
(60–1,100)
3,200 
(1,600–6,000) NA NA
BSI: bloodstream infection; CrI: credible interval; LOS: length of stay; MRSA/MSSA: meticillin-resistant/susceptible Staphylococcus 
aureus; NA: not applicable; 3GC: third-generation cephalosporins; 3GCRE/3GCSE: third-generation cephalosporin-resistant/susceptible 
Enterobacteriaceae.
a Output from probabilistic sensitivity analysis based on input distributions, reproduced to demonstrate consistency with estimates from the 
current study. 
b Estimated for a hospital with 450,000 bed-days annually (95% CrI not displayed because precision from the study cohort is such that no 
additional uncertainty is added to the model). 
c Employs the bed-day valuation derived from a contingent valuation survey that estimated the opportunity cost of each bed-day consumed by 
a patient with BSI. 
d Employs the bed-day valuation computed by dividing total hospital budget for one year by the number of bed-days supplied during the same 
period. Refer to [8] for further details. All costs are displayed at two significant figures.
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however our primary results do not depend on this dis-
tinction. In addition, we could not include antibiotic 
exposure data. However, we consider delayed appropri-
ate antimicrobial therapy to be on the causal pathway 
between antimicrobial resistance and the outcomes 
of interest [27], so exclusion of this information from 
our analysis is appropriate. We were unable to follow 
up patients post discharge, thus cannot report 30-day 
mortality or longer-term sepsis outcomes [28]. As with 
any observational study, we cannot exclude residual 
confounding. Our research question, however, is not 
amenable to an experimental study, and by accounting 
for time-dependent bias and important confounders, 
these results add to the existing literature. Finally, our 
study was designed to evaluate cost from the hospital 
perspective and addressed neither societal costs, mac-
roeconomic indicators, nor the global health-economic 
implications of a post-antibiotic future [29,30].
This multicentre study, conducted in 10 European hos-
pitals, could cautiously be extrapolated to large hospi-
tals in other high-income settings, although the burden 
of BSI will clearly vary depending on incidence, treat-
ment and hospital funding schemes. However, the cur-
rent study did not address the lack of data in this field 
from low- and middle-income countries, where limited 
diagnostic and therapeutic resources, combined with 
lower proportion of gross domestic product available 
for healthcare, are likely to translate to a greater bur-
den of disease.
Our data demonstrate the substantial health and eco-
nomic burden imposed by BSI in European hospitals. 
Per infection, BSI caused by non-susceptible strains 
were associated with higher mortality risk and cost 
than susceptible strains. Given that BSI due to non-
susceptible S. aureus and Enterobacteriaceae strains 
are likely to add to rather than replace those due to 
susceptible strains [31,32], the additional impact of 
AMR is substantial. However, the higher incidence of 
BSI due to susceptible strains means that these cur-
rently represent a greater health and economic burden 
than non-susceptible strains, emphasising the impor-
tance of surveillance and infection control policies that 
target infections rather than resistance.
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